Interestingly, inhibition of nSMase2 also decreases the transfer of oligomeric aggregates of α-synuclein into exosomes and the resulting spreading between neurons, thus suggesting that the inhibitors of nSMase2 might be used as new kinds of drugs for the therapy of PD [307]. Here, SMPD3 is linked to Parkinson disease.